Share story
Capital

Aptadir secures €40 million seed round for RNA therapies

Aptadir secures €40 million seed round for RNA therapies Image: Primary
Aptadir Therapeutics secured a €40 million seed round that includes an investment from CE-Ventures, the venture arm of Crescent Enterprises, CE-Ventures announced Tuesday. The financing will support the preclinical company's work on RNA-based treatments for genetic disorders and oncology, including its lead candidate for Fragile X syndrome. Aptadir's experimental molecules are designed to interfere with abnormal DNA methylation, a process that can silence genes. The company says it has demonstrated gene reactivation in patient-derived disease models. The round gives Aptadir capital to advance its pipeline toward clinical development, but its lead treatment remains preclinical.
Sources
zawya.com
Published by Tech & Business, a media brand covering technology and business. This story was sourced from zawya.com and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Infrastructure
Infrastructure

GlobalFoundries starts construction of Japan-funded New York chip fab

GlobalFoundries says it broke ground November 13 on a new semiconductor factory in Malta, New York, starting construction of the first of two planned fabs under a U.S.-Japan initiative providing up to $21 billion in funding.

Markets Insider
Capital Infrastructure
Capital Infrastructure

Drogue raises $20 million for ocean-powered floating data centers

Drogue has raised $20 million to develop floating data centers powered by ocean temperature differences, the startup told TechCrunch. Investors include XYZ Venture Capital, Toyota Ventures and Tamarack Global.

TechCrunch
Capital AI
Capital AI

ValkaAI extends pre-seed funding round to €13 million

Czech startup ValkaAI has extended its pre-seed funding round to €13 million, with backing from Look AI Ventures and ff Venture Capital. The company announced €12 million in initial external funding in February 2026.

EU-Startups